Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 2/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.37 |
| ▸ | PIK3C3 | Q8NEB9 | 3/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.36 |
| ▸ | TGFBR2 | P37173 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.35 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | BRAF | P15056 | 3/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19133730 | 0.91 | ACACB (0.43) | ACACBPIK3C3TGFBR1TGFBR2CYP1A2 | |
| SCHEMBL17840852 | 0.87 | MAPK14 (0.37) | PIK3C3TGFBR1TGFBR2MAPK14MAPK13 | |
| SCHEMBL25246220 | 0.87 | GRM5 (0.40) | PIK3C3TGFBR1TGFBR2MAPK14MAPK13 | |
| SCHEMBL30365653 | 0.87 | MAPK14 (0.37) | PIK3C3TGFBR1TGFBR2MAPK14MAPK13 | |
| SCHEMBL17840796 | 0.82 | L3MBTL1 (0.40) | PIK3C3TGFBR1MAPK14MAPK13L3MBTL1 | |
| SCHEMBL30365566 | 0.82 | L3MBTL1 (0.40) | PIK3C3TGFBR1MAPK14MAPK13L3MBTL1 | |
| SCHEMBL17840843 | 0.82 | KDR (0.39) | FGFR1PIK3C3TGFBR1CYP1A2CYP2C9 | |
| SCHEMBL17840813 | 0.81 | ACACB (0.42) | ACACBPIK3C3TGFBR1TGFBR2CYP1A2 | |
| SCHEMBL17840563 | 0.81 | CYP1A2 (0.40) | ACACBPIK3C3CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL17840596 | 0.78 | PIK3C3 (0.41) | PIK3C3TGFBR1MAPK14L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3237415-A1 | TGF RECEPTOR ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2017-11-01 | — | — | EP | disclosed |
| US-9708316-B2 | TGFβR antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-07-18 | — | — | US | disclosed |
| US-9708316-B2 | TGFβR antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-07-18 | — | — | US | disclosed |
| WO-2016106266-A1 | TGFβ RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-06-30 | — | — | WO | disclosed |
| WO-2016106266-A1 | TGFβ RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-06-30 | — | — | WO | disclosed |
| US-20160176871-A1 | TGF BETA R ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2016-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160176871-A1 | TGF BETA R ANTAGONISTS | TGFBR2, TGFBR1, TGFB1 | ACACB 2045/4885FGFR1 111/4885PIK3C3 2608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.